UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2021

 

Commission File Number: 001-34541

 

GLOBAL CORD BLOOD CORPORATION

(Translation of registrant’s name into English)

 

48th Floor, Bank of China Tower
1 Garden Road
Central
Hong Kong S.A.R.

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x                       Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

 

 


 

EXPLANATORY NOTE

 

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or Global Cord Blood Corporation’s (the “Company”) future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Report on Form 6-K is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company’s expectations are as of the date of this Report on Form 6-K, and the Company does not intend to update any of the forward-looking statements after the date of this Report on Form 6-K to conform these statements to actual results, unless required by law.

 

The forward-looking statements included in this Report on Form 6-K are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: the effects of the current 2019 novel coronavirus (“COVID-19”) outbreak, including the inability of the Company’s salesforce to return to work due to current lockdowns implemented in various cities in the PRC and the imposition by some hospitals in the PRC of restrictions on entrance to solely to hospital staff and patients; levels of consumer confidence in the healthcare services sector generally in the PRC as a result of the outbreak; the length of the COVID-19 outbreak and severity of such outbreak across the globe; the pace of recovery following the COVID-19 outbreak; continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including maintaining effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of legislative developments affecting U.S. listed issuers whose independent registered public accounting firms are based in the PRC and not subject to U.S. Public Company Accounting Oversight Board inspections, international pressure on trade and currency against the PRC and its potential impact on the PRC consumer behavior, as well as general economic conditions, and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission in the United States.

 

2


 

Results of Operations and Financial Condition

 

Following this cover page are the unaudited condensed consolidated financial results for the three months and nine months ended December 31, 2020 of the Company.

 

3


 

GLOBAL CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31 and December 31, 2020

 

 

 

March 31,

 

December 31,

 

 

 

2020

 

2020

 

 

 

RMB

 

RMB

 

US$

 

 

 

(in thousands except share data)

 

ASSETS

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

Cash and cash equivalents

 

5,473,373

 

5,867,754

 

899,274

 

Accounts receivable, less allowance for doubtful accounts (March 31, 2020: RMB111,869; December 31, 2020: RMB124,205 (US$19,035))

 

104,251

 

128,962

 

19,765

 

Inventories

 

43,758

 

57,095

 

8,750

 

Prepaid expenses and other receivables

 

44,785

 

57,231

 

8,771

 

Total current assets

 

5,666,167

 

6,111,042

 

936,560

 

Property, plant and equipment, net

 

522,679

 

508,924

 

77,996

 

Operating lease right-of-use assets

 

4,548

 

5,573

 

854

 

Non-current deposits

 

347,360

 

343,006

 

52,568

 

Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2020: RMB71,421; December 31, 2020: RMB70,125 (US$10,747))

 

160,031

 

202,658

 

31,059

 

Inventories

 

85,109

 

90,132

 

13,813

 

Intangible assets, net

 

92,823

 

89,357

 

13,695

 

Investment in equity securities at fair value

 

101,306

 

121,951

 

18,690

 

Other equity investment

 

189,129

 

189,129

 

28,985

 

Deferred tax assets

 

50,701

 

53,794

 

8,244

 

Total assets

 

7,219,853

 

7,715,566

 

1,182,464

 

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

Accounts payable

 

19,992

 

9,743

 

1,493

 

Accrued expenses and other payables

 

113,989

 

128,233

 

19,653

 

Operating lease liabilities

 

1,717

 

3,116

 

478

 

Deferred revenue

 

402,751

 

423,350

 

64,881

 

Income tax payable

 

32,329

 

27,038

 

4,144

 

Total current liabilities

 

570,778

 

591,480

 

90,649

 

Non-current deferred revenue

 

2,289,762

 

2,367,446

 

362,827

 

Non-current operating lease liabilities

 

1,782

 

195

 

30

 

Other non-current liabilities

 

450,900

 

473,990

 

72,642

 

Deferred tax liabilities

 

18,140

 

16,990

 

2,604

 

Total liabilities

 

3,331,362

 

3,450,101

 

528,752

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

 

 

 

Shareholders’ equity of Global Cord Blood Corporation

 

 

 

 

 

 

 

Ordinary shares

 

 

 

 

 

 

 

- US$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and December 31, 2020, respectively

 

83

 

83

 

13

 

Additional paid-in capital

 

2,101,582

 

2,101,582

 

322,082

 

Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively)

 

(2,815

)

(2,815

)

(431

)

Accumulated other comprehensive losses

 

(94,663

)

(103,593

)

(15,876

)

Retained earnings

 

1,877,940

 

2,258,453

 

346,122

 

Total equity attributable to Global Cord Blood Corporation

 

3,882,127

 

4,253,710

 

651,910

 

Non-controlling interests

 

6,364

 

11,755

 

1,802

 

Total equity

 

3,888,491

 

4,265,465

 

653,712

 

Total liabilities and equity

 

7,219,853

 

7,715,566

 

1,182,464

 

 

4


 

GLOBAL CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months and Nine Months Ended December 31, 2019 and 2020

 

 

 

Three months ended December 31,

 

Nine months ended December 31,

 

 

 

2019

 

2020

 

2019

 

2020

 

 

 

RMB

 

RMB

 

US$

 

RMB

 

RMB

 

US$

 

 

 

(in thousands except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

334,733

 

290,798

 

44,567

 

921,572

 

857,318

 

131,389

 

Cost of revenues

 

(51,606

)

(44,878

)

(6,878

)

(145,670

)

(133,039

)

(20,389

)

Gross profit

 

283,127

 

245,920

 

37,689

 

775,902

 

724,279

 

111,000

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

(6,404

)

(8,985

)

(1,377

)

(17,504

)

(18,283

)

(2,802

)

Sales and marketing

 

(75,936

)

(68,994

)

(10,574

)

(201,453

)

(178,178

)

(27,307

)

General and administrative

 

(47,914

)

(43,984

)

(6,741

)

(147,251

)

(131,191

)

(20,106

)

Total operating expenses

 

(130,254

)

(121,963

)

(18,692

)

(366,208

)

(327,652

)

(50,215

)

Operating income

 

152,873

 

123,957

 

18,997

 

409,694

 

396,627

 

60,785

 

Other income, net

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

6,350

 

7,190

 

1,102

 

19,072

 

22,767

 

3,489

 

Foreign currency exchange gains/(losses)

 

26

 

75

 

11

 

(164

)

183

 

28

 

Change in fair value of equity securities

 

8,047

 

6,003

 

920

 

10,983

 

30,107

 

4,614

 

Dividend income

 

 

 

 

507

 

1,281

 

196

 

Others

 

4,515

 

2,152

 

330

 

5,277

 

5,070

 

777

 

Total other income, net

 

18,938

 

15,420

 

2,363

 

35,675

 

59,408

 

9,104

 

Income before income tax

 

171,811

 

139,377

 

21,360

 

445,369

 

456,035

 

69,889

 

Income tax expense

 

(25,644

)

(21,220

)

(3,252

)

(67,207

)

(70,131

)

(10,748

)

Net income

 

146,167

 

118,157

 

18,108

 

378,162

 

385,904

 

59,141

 

Net income attributable to non-controlling interests

 

(1,154

)

(1,587

)

(243

)

(4,452

)

(5,391

)

(826

)

Net income attributable to Global Cord Blood Corporation’s shareholders

 

145,013

 

116,570

 

17,865

 

373,710

 

380,513

 

58,315

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

Attributable to ordinary shares

 

 

 

 

 

 

 

 

 

 

 

 

 

- Basic

 

1.19

 

0.96

 

0.15

 

3.07

 

3.13

 

0.48

 

- Diluted

 

1.19

 

0.96

 

0.15

 

3.07

 

3.13

 

0.48

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive losses, net of nil income taxes

 

 

 

 

 

 

 

 

 

 

 

 

 

- Foreign currency translation adjustments

 

(30,953

)

(4,289

)

(657

)

(7,800

)

(8,930

)

(1,369

)

Comprehensive income

 

115,214

 

113,868

 

17,451

 

370,362

 

376,974

 

57,772

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income attributable to non-controlling interests

 

(1,154

)

(1,587

)

(243

)

(4,452

)

(5,391

)

(826

)

Comprehensive income attributable to Global Cord Blood Corporation’s shareholders

 

114,060

 

112,281

 

17,208

 

365,910

 

371,583

 

56,946

 

 

5


 

Other Events

 

On February 24, 2021, the Company issued a press release announcing unaudited condensed consolidated financial results for the three months and nine months ended December 31, 2020. A copy of the press release is attached as Exhibit 99.1.

 

Exhibits

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release dated February 24, 2021

 

6


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

GLOBAL CORD BLOOD CORPORATION

 

 

 

 

By:

/s/ Albert Chen

 

Name:

Albert Chen

 

Title:

Chief Financial Officer

 

 

 

Dated: February 24, 2021

 

 

 

7


Exhibit 99.1

 

 

Global Cord Blood Corporation Reports Financial Results

for the Third Quarter and First Nine Months of Fiscal 2021

 

Added 17,802 New Subscribers in 3Q21

Conference Call to be Held on February 25, 2021, at 8:00 a.m. ET

 

HONG KONG, China, February 24, 2021 — Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine months of fiscal 2021, ended December 31, 2020.

 

Third Quarter Fiscal 2021 Highlights

 

·

Revenues decreased by 13.1% year-over-year (“YoY”) to RMB290.8 million ($44.6 million).

·

New subscribers and accumulated subscriber base were 17,802 and 882,9821, respectively.

·

Gross profit decreased by 13.1% YoY to RMB245.9 million ($37.7 million). Gross margin remained at 84.6%, same as the prior year period.

·

Operating income decreased by 18.9% YoY to RMB124.0 million ($19.0 million). Operating margin decreased to 42.6% from 45.7% in the prior year period.

·

Operating income before depreciation and amortization (“non-GAAP operating income”2) decreased by 17.4% YoY to RMB136.3 million ($20.9 million).

 

·

Net income attributable to the Company’s shareholders decreased by 19.6% to RMB116.6 million ($17.9 million).

·

Net cash provided by operating activities was RMB145.0 million ($22.2 million).

 

Nine Month Fiscal 2021 Highlights

 

·

Revenues decreased by 7.0% YoY to RMB857.3 million ($131.4 million).

·

New subscribers and accumulated subscriber base were 52,678 and 882,9821, respectively.

·

Gross profit decreased by 6.7% YoY to RMB724.3 million ($111.0 million).

·

Operating income decreased by 3.2% YoY to RMB396.6 million ($60.8 million).

·

Non-GAAP operating income2 decreased by 3.0% YoY to RMB433.5 million ($66.4 million).

·

Net income attributable to the Company’s shareholders increased by 1.8% to RMB380.5 million ($58.3 million), mainly due to the increase in fair value of equity securities (“mark-to-market gains”).

·

Net cash provided by operating activities was RMB419.6 million ($64.3 million).

 

“Despite the ongoing challenges due to COVID-19, lower newborn numbers, and cautious consumer sentiment, we managed to recruit 17,802 new subscribers in the third quarter, keeping us on track to meet our annual target,” said Ms. Ting Zheng, Chief Executive Officer and Chairperson of GCBC. “Although the National Health Commission announced a new policy that no cord blood banking license applications would be accepted in 2021, new developments on industry regulations remain largely uncertain. As such, we must continue to communicate with regulatory bodies and remain vigilant regarding other changes that may arise within the industry. We intend to leverage our advantages as the industry leader to increase penetration in existing markets and seize available opportunities to expand our business and services.”

 


 

Summary — Third Quarter and Nine Months Ended December 31, 2019 and 2020

 

 

 

Three Months Ended December 31,

 

Nine Months Ended December 31,

 

 

 

2019

 

2020

 

2019

 

2020

 

(in thousands)

 

RMB

 

RMB

 

US$

 

RMB

 

RMB

 

US$

 

Revenues

 

334,733

 

290,798

 

44,567

 

921,572

 

857,318

 

131,389

 

Gross Profit

 

283,127

 

245,920

 

37,689

 

775,902

 

724,279

 

111,000

 

Operating Income3

 

152,873

 

123,957

 

18,997

 

409,694

 

396,627

 

60,785

 

Change in Fair Value of Equity Securities

 

8,047

 

6,003

 

920

 

10,983

 

30,107

 

4,614

 

Net Income Attributable to the Company’s Shareholders

 

145,013

 

116,570

 

17,865

 

373,710

 

380,513

 

58,315

 

Earnings per Ordinary Share (RMB/US$)

 

 

 

 

 

 

 

 

 

 

 

 

 

– Basic

 

1.19

 

0.96

 

0.15

 

3.07

 

3.13

 

0.48

 

– Diluted

 

1.19

 

0.96

 

0.15

 

3.07

 

3.13

 

0.48

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues Breakdown (%)

 

 

 

 

 

 

 

 

 

 

 

 

 

Processing Fees and Other Services

 

65.3

%

56.8

%

 

 

63.6

%

57.3

%

 

 

Storage Fees

 

34.7

%

43.2

%

 

 

36.4

%

42.7

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

New Subscribers (persons)

 

23,387

 

17,802

 

 

 

65,753

 

52,678

 

 

 

Total Accumulated Subscribers (persons)

 

815,000

 

882,982

1

 

 

815,000

 

882,982

1

 

 

 

Summary — Selected Cash Flow Statement Items

 

 

 

Three Months Ended December 31,

 

Nine Months Ended December 31,

 

 

 

2019

 

2020

 

2019

 

2020

 

(in thousands)

 

RMB

 

RMB

 

US$

 

RMB

 

RMB

 

US$

 

Net cash provided by operating activities

 

156,031

 

144,988

 

22,222

 

534,042

 

419,631

 

64,313

 

Net cash used in investing activities

 

(139,806

)

(5,996

)

(919

)

(145,035

)

(17,316

)

(2,654

)

Net cash used in financing activities

 

 

 

 

(4,039

)

(6,074

)

(931

)

 

Third Quarter Fiscal 2021 Financial Results

 

REVENUES. Revenues decreased by 13.1% YoY to RMB290.8 million ($44.6 million) in the third quarter of fiscal 2021, mainly due to a drop in new subscribers which resulted in lower revenues from processing fees and other services.

 

During the reporting quarter, the 2019 novel coronavirus (“COVID-19”) pandemic continued to affect the Company’s hospital channels and business operations. In addition, newborn numbers in the Company’s operating markets remained on a downward trend. These factors led to a 23.9% YoY decrease in new subscribers to 17,802. Revenues generated from processing fees and other services in the reporting quarter decreased by 24.4% YoY to RMB165.2 million ($25.3 million), representing 56.8% of total revenues compared to 65.3% in the prior year period.

 

As of December 31, 2020, the accumulated subscriber base had expanded to 882,9821. Revenues generated from storage fees increased by 8.0% YoY to RMB125.6 million ($19.3 million) in the reporting quarter.

 


 

GROSS PROFIT. Gross profit for the third quarter decreased by 13.1% YoY to RMB245.9 million ($37.7 million). As general cost reductions resulting from lower volumes were offset by higher costs associated with raw material and labor, gross margin remained at 84.6%, same as in the prior year period.

 

OPERATING INCOME. Operating income for the reporting quarter decreased by 18.9% YoY to RMB124.0 million ($19.0 million). Operating margin was 42.6% compared to 45.7% in the prior year period. Depreciation and amortization expenses for the third quarter were RMB12.3 million ($1.9 million), compared to RMB12.1 million in the prior year period. Non-GAAP operating income2 decreased by 17.4% YoY to RMB136.3 million ($20.9 million) in the reporting quarter.

 

Research and Development Expenses. As the Company continued to support science and technology advancement related to the utilization of cord blood stem cells through old and new collaborations, research and development expenses in the third quarter increased to RMB9.0 million ($1.4 million) from RMB6.4 million in the prior year period.

 

Sales and Marketing Expenses. During the reporting quarter, the Company enhanced its marketing and promotional efforts, resulting in higher advertising and promotional expenses. The impact was, however, partially offset by lower staff renumeration on the back of a smaller salesforce. As a result, sales and marketing expenses decreased by 9.1% YoY to RMB69.0 million ($10.6 million).

 

General and Administrative Expenses. General and administrative expenses decreased by 8.2% YoY to RMB44.0 million ($6.7 million) due to reduced staff costs and professional fees while partially offset by higher provisions. General and administrative expenses as a percentage of revenues was 15.1% compared to 14.3% in the prior year period.

 

OTHER INCOME.

 

Change in fair value of equity securities. In the reporting period, the Company recognized a mark-to-market gain of RMB6.0 million ($0.9 million), compared to a mark-to-market gain of RMB8.0 million in the prior year period. The changes were mainly attributable to the Company’s investments in equity securities.

 

NET INCOME ATTRIBUTABLE TO THE COMPANY’S SHAREHOLDERS. Income before income tax for the third quarter decreased by 18.9% YoY to RMB139.4 million ($21.4 million). Income tax expense for the third quarter was RMB21.2 million ($3.3 million). Net income attributable to the Company’s shareholders for the reporting quarter decreased by 19.6% YoY to RMB116.6 million ($17.9 million). Net margin for the reporting quarter was 40.1%.

 

EARNINGS PER SHARE. Basic and diluted earnings per ordinary share for the third quarter of fiscal 2021 was RMB0.96 ($0.15).

 

Nine Month Fiscal 2021 Financial Results

 

Total revenues for the first nine months of fiscal 2021 decreased by 7.0% YoY to RMB857.3 million ($131.4 million). The decrease was mainly due to the decline in new subscribers. Revenues from processing fees and other services decreased by 16.3% YoY to RMB491.1 million ($75.3 million), whereas revenues from storage fees increased by 9.2% YoY to RMB366.2 million ($56.1 million). Gross profit decreased by 6.7% YoY to RMB724.3 million ($111.0 million). Operating income decreased by 3.2% YoY to RMB396.6 million ($60.8 million). Non-GAAP operating income2 decreased by 3.0% YoY to RMB433.5 million ($66.4 million). Net income attributable to the Company’s shareholders improved by 1.8% to RMB380.5 million ($58.3 million). Basic and diluted earnings per ordinary share increased to RMB3.13 ($0.48). Net cash provided by operating activities in the first nine months of fiscal 2021 was RMB419.6 million ($64.3 million).

 

Corporate Developments

 

·                  On June 4, 2019, the Board of Directors of the Company (the “Board”) received a non-binding proposal letter (the “Cordlife Proposal”) from Cordlife Group Limited (“Cordlife”), a company listed on the Mainboard of the Singapore Exchange Securities Trading Limited (“SGX”), pursuant to which Cordlife proposed to combine its business with that of the Company, by way of a statutory merger.

 


 

According to the Cordlife Proposal, Cordlife would issue approximately 2,497.9 million ordinary shares at an issue price of SGD0.5 per ordinary share in exchange for all of the Company’s outstanding ordinary shares at $7.50 per ordinary share. Upon completion of the proposed transaction, the Company’s ordinary shares would be delisted from the New York Stock Exchange, and Cordlife ordinary shares would continue to trade on the SGX. On June 5, 2019, the Board formed a special committee of independent directors (the “Special Committee”), unaffiliated with Cordlife, to evaluate such proposal.

 

On November 11, 2019, the Company appointed Mr. Jack Chow as an independent non-executive director (“INED”) of the Board. Mr. Chow has extensive professional experience and a broad network in the finance and investment industry. He replaced Mr. Mark Chen as a member of the Audit Committee and Ms. Jennifer Weng as a member of the Special Committee. Mr. Chow also joined the Board’s Compensation Committee and Nominating and Corporate Governance Committee.

 

On February 6, 2020, the Company appointed Mr. Jacky Cheng as an INED of the Board. Mr. Cheng has extensive professional experience and knowledge of legal and compliance as well as Chinese laws. He joined as a member of both the Board’s Compensation Committee and the Company’s Special Committee. Currently, the Special Committee is composed of four members, including Mr. Mark Chen, Dr. Ken Lu, Mr. Jack Chow, and Mr. Jacky Cheng.

 

On February 11, 2021, the Company announced that the Board and the board of Cordlife have mutually agreed to discontinue any further discussions regarding the Cordlife Proposal.

 

Conference Call

 

The Company will host a conference call at 8:00 a.m. ET on Thursday, February 25, 2021, to discuss its financial performance and give a brief overview of the Company’s recent developments, followed by a question-and-answer session. Interested parties can access the audio webcast through the Company’s IR website at http://ir.globalcordbloodcorporation.com. A replay of the webcast will be accessible two hours after the conference call and available for seven days at the same URL above. Listeners can also access the call by dialing 1-646-722-4977 or 1-855-824-5644 for US callers, or +852-3027-6500 for Hong Kong callers, access code: 28530146#.

 


1 During the three months and nine months ended December 31, 2020, 17,802 and 52,678 new subscribers were recruited, respectively. During the three months and nine months ended December 31, 2020, the Company determined that the recoverability of 2,000 and 2,790 private cord blood units was remote; therefore, the Company terminated their subscription services according to the subscription contracts. Out of these prior private cord blood units, 1,600 and 2,390 prior private cord blood units were being treated as if they were donated cord blood units and will be part of the Company’s non-current inventories. Hence, the net accumulated subscriber base was 882,982 as of December 31, 2020.

 

2 See exhibit 3 to this press release for a reconciliation of non-GAAP operating income to exclude the non-cash items related to the depreciation and amortization expenses to the comparable financial measure prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).

 

3 The reported operating income for the three months ended December 31, 2019 and 2020 included depreciation and amortization expenses related to property, plant and equipment and intangible assets of RMB12.1 million and RMB12.3 million ($1.9 million), respectively. The reported operating income for the nine months ended December 31, 2019 and 2020 included depreciation and amortization expenses related to property, plant and equipment and intangible assets of RMB37.0 million and RMB36.9 million ($5.7 million), respectively.

 


 

Use of Non-GAAP Financial Measures

 

GAAP results for the three months and nine months ended December 31, 2020, include non-cash items related to depreciation and amortization expenses. To supplement the Company’s unaudited condensed consolidated financial statements presented on a U.S. GAAP basis, the Company has provided adjusted financial information excluding the impact of these items in this press release. The non-GAAP financial measure represents non-GAAP operating income. Such adjustment is a departure of U.S. GAAP; however, the Company’s management believes that these adjusted measures provide investors with a better understanding of how the results relate to the Company’s historical performance. Also, management uses non-GAAP operating income as a measurement tool for evaluating actual operating performance compared to budget and prior periods. These adjusted measures should not be considered an alternative to operating income, or any other measure of financial performance or liquidity presented in accordance with U.S. GAAP. These measures are not necessarily comparable to a similarly titled measure of another company. A reconciliation of the adjustments to U.S. GAAP results appears in exhibit 3 accompanying this press release. This additional adjusted information is not meant to be considered in isolation or as a substitute for U.S. GAAP financials. The adjusted financial information that the Company provides also may differ from the adjusted information provided by other companies.

 

About Global Cord Blood Corporation

 

Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company’s website at: http://www.globalcordbloodcorporation.com.

 

Safe Harbor Statement

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company’s future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.

 

The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: the effects of the current COVID-19 outbreak, including the inability of the Company’s salesforce to return to work due to current lockdowns implemented in various cities in the PRC and the imposition by some hospitals in the PRC of restrictions on entrance to solely to hospital staff and patients; levels of consumer confidence in the healthcare services sector generally in the PRC as a result of the outbreak; the length of the COVID-19 outbreak and severity of such outbreak across the globe; the pace of recovery following the COVID-19 outbreak; continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including maintaining effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of legislative developments in the U.S. affecting listed issuers whose independent registered public accounting firms are based in China and not subject to U.S. Public Company Accounting Oversight Board inspections, international pressure on trade and currency against the PRC and its potential impact on the PRC consumer behavior, as well as general economic conditions, and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission in the United States.

 


 

This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the period ended December 31, 2020 were made at the noon buying rate of RMB6.5250 to $1.00 on December 31, 2020 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. Global Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

 

For more information, please contact:

 

Global Cord Blood Corporation

Investor Relations Department

Tel: (+852) 3605-8180

Email: [email protected]

 

ICR, Inc.

William Zima

Tel: (+86) 10-6583-7511

U.S. Tel: (646) 405-5185

Email: [email protected]

 


 

EXHIBIT 1

 

GLOBAL CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31 and December 31, 2020

 

 

 

March 31,

 

December 31,

 

 

 

2020

 

2020

 

 

 

RMB

 

RMB

 

US$

 

 

 

(in thousands except share data)

 

ASSETS

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

Cash and cash equivalents

 

5,473,373

 

5,867,754

 

899,274

 

Accounts receivable, less allowance for doubtful accounts (March 31, 2020: RMB111,869; December 31, 2020: RMB124,205 (US$19,035))

 

104,251

 

128,962

 

19,765

 

Inventories

 

43,758

 

57,095

 

8,750

 

Prepaid expenses and other receivables

 

44,785

 

57,231

 

8,771

 

Total current assets

 

5,666,167

 

6,111,042

 

936,560

 

Property, plant and equipment, net

 

522,679

 

508,924

 

77,996

 

Operating lease right-of-use assets

 

4,548

 

5,573

 

854

 

Non-current deposits

 

347,360

 

343,006

 

52,568

 

Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2020: RMB71,421; December 31, 2020: RMB70,125 (US$10,747))

 

160,031

 

202,658

 

31,059

 

Inventories

 

85,109

 

90,132

 

13,813

 

Intangible assets, net

 

92,823

 

89,357

 

13,695

 

Investment in equity securities at fair value

 

101,306

 

121,951

 

18,690

 

Other equity investment

 

189,129

 

189,129

 

28,985

 

Deferred tax assets

 

50,701

 

53,794

 

8,244

 

Total assets

 

7,219,853

 

7,715,566

 

1,182,464

 

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

Accounts payable

 

19,992

 

9,743

 

1,493

 

Accrued expenses and other payables

 

113,989

 

128,233

 

19,653

 

Operating lease liabilities

 

1,717

 

3,116

 

478

 

Deferred revenue

 

402,751

 

423,350

 

64,881

 

Income tax payable

 

32,329

 

27,038

 

4,144

 

Total current liabilities

 

570,778

 

591,480

 

90,649

 

Non-current deferred revenue

 

2,289,762

 

2,367,446

 

362,827

 

Non-current operating lease liabilities

 

1,782

 

195

 

30

 

Other non-current liabilities

 

450,900

 

473,990

 

72,642

 

Deferred tax liabilities

 

18,140

 

16,990

 

2,604

 

Total liabilities

 

3,331,362

 

3,450,101

 

528,752

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

 

 

 

Shareholders’ equity of Global Cord Blood Corporation

 

 

 

 

 

 

 

Ordinary shares

 

 

 

 

 

 

 

 - US$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and December 31, 2020, respectively

 

83

 

83

 

13

 

Additional paid-in capital

 

2,101,582

 

2,101,582

 

322,082

 

Treasury stock, at cost (March 31 and December 31, 2020: 136,899 shares, respectively)

 

(2,815

)

(2,815

)

(431

)

Accumulated other comprehensive losses

 

(94,663

)

(103,593

)

(15,876

)

Retained earnings

 

1,877,940

 

2,258,453

 

346,122

 

Total equity attributable to Global Cord Blood Corporation

 

3,882,127

 

4,253,710

 

651,910

 

Non-controlling interests

 

6,364

 

11,755

 

1,802

 

Total equity

 

3,888,491

 

4,265,465

 

653,712

 

Total liabilities and equity

 

7,219,853

 

7,715,566

 

1,182,464

 

 


 

EXHIBIT 2

 

GLOBAL CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months and Nine Months Ended December 31, 2019 and 2020

 

 

 

Three months ended December 31,

 

Nine months ended December 31,

 

 

 

2019

 

2020

 

2019

 

2020

 

 

 

RMB

 

RMB

 

US$

 

RMB

 

RMB

 

US$

 

 

 

(in thousands except per share data)

 

Revenues

 

334,733

 

290,798

 

44,567

 

921,572

 

857,318

 

131,389

 

Cost of revenues

 

(51,606

)

(44,878

)

(6,878

)

(145,670

)

(133,039

)

(20,389

)

Gross profit

 

283,127

 

245,920

 

37,689

 

775,902

 

724,279

 

111,000

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

(6,404

)

(8,985

)

(1,377

)

(17,504

)

(18,283

)

(2,802

)

Sales and marketing

 

(75,936

)

(68,994

)

(10,574

)

(201,453

)

(178,178

)

(27,307

)

General and administrative

 

(47,914

)

(43,984

)

(6,741

)

(147,251

)

(131,191

)

(20,106

)

Total operating expenses

 

(130,254

)

(121,963

)

(18,692

)

(366,208

)

(327,652

)

(50,215

)

Operating income

 

152,873

 

123,957

 

18,997

 

409,694

 

396,627

 

60,785

 

Other income, net

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

6,350

 

7,190

 

1,102

 

19,072

 

22,767

 

3,489

 

Foreign currency exchange gains/(losses)

 

26

 

75

 

11

 

(164

)

183

 

28

 

Change in fair value of equity securities

 

8,047

 

6,003

 

920

 

10,983

 

30,107

 

4,614

 

Dividend income

 

 

 

 

507

 

1,281

 

196

 

Others

 

4,515

 

2,152

 

330

 

5,277

 

5,070

 

777

 

Total other income, net

 

18,938

 

15,420

 

2,363

 

35,675

 

59,408

 

9,104

 

Income before income tax

 

171,811

 

139,377

 

21,360

 

445,369

 

456,035

 

69,889

 

Income tax expense

 

(25,644

)

(21,220

)

(3,252

)

(67,207

)

(70,131

)

(10,748

)

Net income

 

146,167

 

118,157

 

18,108

 

378,162

 

385,904

 

59,141

 

Net income attributable to non-controlling interests

 

(1,154

)

(1,587

)

(243

)

(4,452

)

(5,391

)

(826

)

Net income attributable to Global Cord Blood Corporation’s shareholders

 

145,013

 

116,570

 

17,865

 

373,710

 

380,513

 

58,315

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

Attributable to ordinary shares

 

 

 

 

 

 

 

 

 

 

 

 

 

- Basic

 

1.19

 

0.96

 

0.15

 

3.07

 

3.13

 

0.48

 

- Diluted

 

1.19

 

0.96

 

0.15

 

3.07

 

3.13

 

0.48

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive losses, net of nil income taxes

 

 

 

 

 

 

 

 

 

 

 

 

 

- Foreign currency translation adjustments

 

(30,953

)

(4,289

)

(657

)

(7,800

)

(8,930

)

(1,369

)

Comprehensive income

 

115,214

 

113,868

 

17,451

 

370,362

 

376,974

 

57,772

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income attributable to non-controlling interests

 

(1,154

)

(1,587

)

(243

)

(4,452

)

(5,391

)

(826

)

Comprehensive income attributable to Global Cord Blood Corporation’s shareholders

 

114,060

 

112,281

 

17,208

 

365,910

 

371,583

 

56,946

 

 


 

EXHIBIT 3

 

GLOBAL CORD BLOOD CORPORATION

RECONCILIATION OF NON-GAAP OPERATING INCOME

For the Three Months and Nine Months Ended December 31, 2019 and 2020

 

 

 

Three months ended
December 31,

 

Nine months ended
December 31,

 

 

 

2019

 

2020

 

2019

 

2020

 

 

 

RMB

 

RMB

 

US$

 

RMB

 

RMB

 

US$

 

 

 

(in thousands)

 

GAAP amount of operating income

 

152,873

 

123,957

 

18,997

 

409,694

 

396,627

 

60,785

 

Depreciation and amortization expenses4

 

12,140

 

12,297

 

1,885

 

37,040

 

36,919

 

5,658

 

Non-GAAP operating income

 

165,013

 

136,254

 

20,882

 

446,734

 

433,546

 

66,443

 

 


4 Depreciation and amortization expenses relate to property, plant and equipment and intangible assets respectively.